ResearcherUniversity of VeronaActive in the last 2 years

Isacco Ferrarini

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-9867-8335; OpenAlex author ID A5007303823. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 2

Papers, trials and grants by year

2021: 1 paper · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper

Papers 2

Correction: ONC212 is a Novel Mitocan Acting Synergistically with Glycolysis Inhibition in Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-26-0613 ↗
ONC212 is a Novel Mitocan Acting Synergistically with Glycolysis Inhibition in Pancreatic Cancer. Co-author DOI 10.1158/1535-7163.mct-20-0962 ↗

Closest collaborators

The 2 strongest of 2 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Anna D. Louie · 2 shared papers, 2021–2026 · strength 0.62
- Paper Correction: ONC212 is a Novel Mitocan Acting Synergistically with Glycolysis Inhibition in Pancreatic Cancer. DOI 10.1158/1535-7163.mct-26-0613 ↗
- Paper ONC212 is a Novel Mitocan Acting Synergistically with Glycolysis Inhibition in Pancreatic Cancer. DOI 10.1158/1535-7163.mct-20-0962 ↗
Wafik S. El‐Deiry · 2 shared papers, 2021–2026 · strength 0.62
- Paper Correction: ONC212 is a Novel Mitocan Acting Synergistically with Glycolysis Inhibition in Pancreatic Cancer. DOI 10.1158/1535-7163.mct-26-0613 ↗
- Paper ONC212 is a Novel Mitocan Acting Synergistically with Glycolysis Inhibition in Pancreatic Cancer. DOI 10.1158/1535-7163.mct-20-0962 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.